Fundamental Analysis of XENON PHARMACEUTICALS INC(NASDAQ:XENE) stock

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to XENE. XENE was compared to 588 industry peers in the Biotechnology industry. XENE has a great financial health rating, but its profitability evaluates not so good. XENE does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year XENE has reported negative net income.

In the past year XENE has reported a negative cash flow from operations.

In the past 5 years XENE always reported negative net income.

XENE had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

XENE's Return On Assets of -18.90% is amongst the best of the industry. XENE outperforms 83.79% of its industry peers.

XENE has a better Return On Equity (-19.66%) than 87.54% of its industry peers.

		Industry Rank	Sector Rank
ROA	-18.9%
ROE	-19.66%
ROIC	N/A

ROA(3y)-16.32%

ROA(5y)-18.17%

ROE(3y)-17%

ROE(5y)-22.17%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for XENE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

XENE does not have a ROIC to compare to the WACC, probably because it is not profitable.

XENE has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, XENE has more shares outstanding

There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 51.22 indicates that XENE is not in any danger for bankruptcy at the moment.

XENE has a better Altman-Z score (51.22) than 97.95% of its industry peers.

There is no outstanding debt for XENE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	51.22

ROIC/WACCN/A

WACC8.08%

2.3 Liquidity

A Current Ratio of 23.65 indicates that XENE has no problem at all paying its short term obligations.

XENE has a Current ratio of 23.65. This is amongst the best in the industry. XENE outperforms 96.59% of its industry peers.

A Quick Ratio of 23.65 indicates that XENE has no problem at all paying its short term obligations.

XENE's Quick ratio of 23.65 is amongst the best of the industry. XENE outperforms 96.59% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	23.65
Quick Ratio	23.65

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for XENE have decreased strongly by -33.33% in the last year.

XENE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

EPS 1Y (TTM)-33.33%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-12.28%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 22.20% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 208.06% on average over the next years. This is a very strong growth

EPS Next Y-9.24%

EPS Next 2Y-11.08%

EPS Next 3Y-6.09%

EPS Next 5Y22.2%

Revenue Next Year23.89%

Revenue Next 2Y65.07%

Revenue Next 3Y236.56%

Revenue Next 5Y208.06%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

XENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year XENE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

XENE's earnings are expected to decrease with -6.09% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-11.08%

EPS Next 3Y-6.09%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for XENE!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

XENON PHARMACEUTICALS INC

NASDAQ:XENE (5/2/2024, 7:00:03 PM)

After market: 43 0 (0%)

+0.51 (+1.2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap3.24B

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-18.9%
ROE	-19.66%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	23.65
Quick Ratio	23.65
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-33.33%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-9.24%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

XENON PHARMACEUTICALS INC (XENE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens